CD274 and neoplasm: However, evaluation of PD-L1 expression on tumor cells is currently the only biomarker approved to select patients for treatment with PD1/PD-L1 axis inhibitors, with several limitations due to tumor heterogeneity (19), differences between clones (20) and types of material (21).